VANCOUVER, British Columbia, April 09, 2019 (GLOBE NEWSWIRE) -- Chemesis International Inc. (CSE:
CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or “Chemesis”), announces it will produce and distribute its
all-natural CBD product line Viverian, in Puerto Rico, through its subsidiary Natural Ventures.
Viverian is a hemp-derived CBD product line that promotes healthy living and provides consumers with quick and
easy methods of consumption. The product line includes CBD tinctures, as well as capsules that may assist with sleep, relaxation,
improved concentration, relief for discomfort, and improved overall health and wellness. These products have been lab tested, are
THC free, and made of 100% botanical ingredients.
New regulations from the Puerto Rican Department of Health will allow Natural Venture to utilize its
high-quality manufacturing facility. The new regulations allow licensed manufacturing facilities to incorporate hemp derived CBD in
to its portfolios as long as the products are entered in to the tracking system and tested through licensed labs in Puerto
Rico.
Natural Ventures anticipates Viverian products will be available in dispensaries before April 30th,
and will also offer contract manufacturing services for other licensees in Puerto Rico.
“Natural Ventures is a key part of Chemesis’ long term strategy to build a major presence in Latin America, and
by launching Viverian, it allows penetration into the Puerto Rican CBD market,” said CEO of Chemesis, Edgar Montero. “Chemesis
believes it has an advantage in the Latin American CBD market as it is able to leverage its state-of-the-art facility, its
previously announced partnership with First Medical that brings up to 6,000 acres of hemp cultivation, and
its all-natural Viverian CBD product catalogue.”
For more information on the products, please visit www.viverian.com
On Behalf of The Board of Directors
Edgar Montero
CEO and Director
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently
operating within California, Puerto Rico, and Colombia.
Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution and
retail. Chemesis has facilities in both Puerto Rico and California, allowing for cost effective production and distribution of its
products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods to
provide consumers with quality cannabis products.
Chemesis will add shareholder value by exploring opportunities in emerging markets while consistently delivering
quality product to its consumers from seed to sale.
Investor Relations:
ir@chemesis.com
1 (604) 398-3378
Social Media:
Chemesis.facebook
Chemesis.twitter
Chemesis.instagram
DesertZen.instagram
CaliforniaSap.instagram
Jay&SB.instagram
Forward-Looking Information: This news release contains "forward-looking
information" within the meaning of applicable securities laws relating to statements regarding the transactions contemplated by the
Agreement and the Company's business, products and future of the Company’s business, its expansion plans, product offerings and
plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are
reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue
reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause
actual results, performance and developments to differ materially from those contemplated by these statements, including, among
other things, the risks that the transactions contemplated by the Agreement will not complete as anticipated, or at all, that the
Company's products and plans, particularly with respect to expansion into retail and other opportunities, will vary from those
stated in this news release, that the anticipated benefits of the proposed alliance with GSRX will not materialize as expected, or
at all, and that the Company may not be able to carry out its business plans as expected. Except as required by law, the Company
expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in
this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable,
there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales
reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release
